Clinical trials data
Delay Discounting in substance use and addiction trials: 104 registered studies
Every registered substance use and addiction study on ClinicalTrials.gov that names Delay Discounting in an outcome measure: how often it is a primary outcome, the tests named with it, how large the studies are and when they measure it.
- Registered substance use and addiction studies name it in an outcome measure
- 104
- Name it in a primary outcome, 33%
- 34 of 104
Tests named in the same studies
- 1
Purchase Task14 studies, 3 as a primary outcome
- 2
Stop-Signal Task11 studies, 2 as a primary outcome
- 3
Balloon Risk9 studies, 0 as a primary outcome
- 4
Digit Span Test7 studies, 4 as a primary outcome
- 5
N-Back Task6 studies, 3 as a primary outcome
- 6
Stroop Color-Word Test6 studies, 2 as a primary outcome
- 7
Card Sorting Test (Berg)5 studies, 3 as a primary outcome
- 8
Go/No-Go Task5 studies, 2 as a primary outcome
- 9
Letter-Number Sequencing Task4 studies, 2 as a primary outcome
- 10
Iowa Gambling Lite4 studies, 1 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
Studies by start year
A test as a primary outcomeOnly in secondary or other outcomes
Show as a table
| Start year | Studies | A test as a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 2 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 3 | 1 |
| 2014 | 3 | 2 |
| 2015 | 3 | 0 |
| 2016 | 4 | 3 |
| 2017 | 5 | 1 |
| 2018 | 11 | 1 |
| 2019 | 9 | 0 |
| 2020 | 9 | 6 |
| 2021 | 9 | 2 |
| 2022 | 7 | 2 |
| 2023 | 9 | 4 |
| 2024 | 10 | 3 |
| 2025 | 8 | 4 |
| 2026 | 9 | 4 |
Phases and study sizes
By phase
- Early phase 14 studies, 0 as a primary outcome
- Phase 16 studies, 3 as a primary outcome
- Phase 1/23 studies, 0 as a primary outcome
- Phase 213 studies, 4 as a primary outcome
- Phase 31 studies, 0 as a primary outcome
- Phase 42 studies, 1 as a primary outcome
- Not applicable69 studies, 21 as a primary outcome
- Observational6 studies, 5 as a primary outcome
Participants per study
- Phase 276 median, 41 to 151
- Not applicable71 median, 40 to 126
Show as a table
| Phase | Studies with a size | Median | Middle half |
|---|---|---|---|
| Phase 2 | 12 | 76 | 41 to 151 |
| Not applicable | 67 | 71 | 40 to 126 |
When substance use and addiction trials measure it
Latest time point of each outcome
- Within a day16 outcomes, 7 as a primary outcome
- Up to 4 weeks35 outcomes, 13 as a primary outcome
- 1 to 3 months26 outcomes, 6 as a primary outcome
- 3 to 6 months11 outcomes, 1 as a primary outcome
- 6 to 12 months5 outcomes, 0 as a primary outcome
- 1 to 2 years2 outcomes, 0 as a primary outcome
- Over 2 years3 outcomes, 3 as a primary outcome
- No duration given5 outcomes, 4 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
98 of the 103 outcome measures give a duration. A single visit counts as within a day.
Status, results, interventions and countries
Status
- Recruiting17 studies, 7 as a primary outcome
- Not yet recruiting4 studies, 1 as a primary outcome
- Active, not recruiting6 studies, 0 as a primary outcome
- Completed59 studies, 18 as a primary outcome
- Stopped early14 studies, 7 as a primary outcome
- Status unknown4 studies, 1 as a primary outcome
What they test
- Behavioral53 studies, 16 as a primary outcome
- Drug29 studies, 12 as a primary outcome
- Device20 studies, 7 as a primary outcome
- Procedure2 studies, 0 as a primary outcome
- Other16 studies, 6 as a primary outcome
- None given3 studies, 2 as a primary outcome
Intervention types as registered. A study can list several; observational studies often list none.
Where their sites are
- United States83 studies, 29 as a primary outcome
- China4 studies, 0 as a primary outcome
- Spain4 studies, 0 as a primary outcome
- Switzerland2 studies, 1 as a primary outcome
- Germany1 studies, 1 as a primary outcome
- Hong Kong1 studies, 0 as a primary outcome
- Puerto Rico1 studies, 1 as a primary outcome
- Sweden1 studies, 0 as a primary outcome
- Uganda1 studies, 0 as a primary outcome
- United Kingdom1 studies, 0 as a primary outcome
10 countries in all. A study with sites in several counts in each; 6 list no site.
Reported results
Completed studies with results posted on ClinicalTrials.gov, a results paper the registry links to the study, or both.
Completed substance use and addiction studies that name Delay Discounting: 36 of 59, 61%
Every completed study with a cognitive outcome: 3,626 of 7,953, 46%
| Results | Completed substance use and addiction studies that name Delay Discounting | Every completed study |
|---|---|---|
| Results on ClinicalTrials.gov and a paper | 10, 17% | 776, 10% |
| Results on ClinicalTrials.gov only | 18, 31% | 1,139, 14% |
| A results paper only | 8, 14% | 1,711, 22% |
| Neither | 23, 39% | 4,327, 54% |
The 104 studies
104 studies match. 34 name Delay Discounting in a primary outcome. Median size 64 participants. Median time to the primary outcome: 4 weeks.
Loading 104 studies; the filters turn on when they arrive.
2026 is partly planned starts. Not shown: 2 planned to start after 2026.
Show as a table
| Start year | Studies | As a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 2 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 3 | 1 |
| 2014 | 3 | 2 |
| 2015 | 3 | 0 |
| 2016 | 4 | 3 |
| 2017 | 5 | 1 |
| 2018 | 11 | 1 |
| 2019 | 9 | 0 |
| 2020 | 9 | 6 |
| 2021 | 9 | 2 |
| 2022 | 7 | 2 |
| 2023 | 9 | 4 |
| 2024 | 10 | 3 |
| 2025 | 8 | 4 |
| 2026 | 9 | 4 |
Library tests named most
Conditions
Phases
Participants
Lead sponsor: industry 2, other 102. Interventional 98, observational 6.
As a primary outcomeSecondary or other outcomeDelay Discounting
The studies, newest registration first
Each number opens the study's record on ClinicalTrials.gov.
| Study | Start | Phase | Conditions | Participants | Lead sponsor | Status | Library tests named, with the latest time point |
|---|---|---|---|---|---|---|---|
| NCT07802223 | Start2026 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants50 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07736742 | Start2026 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants40 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07503782 | Start2026 | PhasePhase 2 | ConditionsSubstance use and addiction | Participants42 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07479771 | Start2026 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants53 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT07341230 | Start2025 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants9 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07178158 | Start2026 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants40 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07171359 | Start2027 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants60 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07158853 | Start2026 | PhasePhase 1 | ConditionsSubstance use and addiction | Participants40 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06988371 | Start2025 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants747 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06981195 | Start2025 | PhasePhase 2 | ConditionsSubstance use and addiction, Sleep and sleep disorders | Participants100 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06771843 | Start2025 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants716 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06712446 | Start2025 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants14 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06629493 | Start2022 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants90 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06629467 | Start2023 | PhaseNot applicable | ConditionsAging, frailty and exercise, Substance use and addiction | Participants128 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06628622 | Start2025 | PhasePhase 1 | ConditionsSubstance use and addiction | Participants12 | Lead sponsorIndustry | StatusStopped early | Library tests named
|
| NCT06381180 | Start2025 | PhasePhase 1/2 | ConditionsSubstance use and addiction, Anxiety, PTSD and OCD | Participants500 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06349083 | Start2026 | PhasePhase 2 | ConditionsSubstance use and addiction | Participants200 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06326684 | Start2024 | PhaseEarly phase 1 | ConditionsSubstance use and addiction | Participants30 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06286774 | Start2024 | PhaseNot applicable | ConditionsSubstance use and addiction, Sleep and sleep disorders | Participants256 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06265506 | Start2024 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants200 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06242704 | Start2024 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants72 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06234722 | Start2024 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants473 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06228235 | Start2024 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants20 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06221839 | Start2026 | PhaseObservational | ConditionsSubstance use and addiction | Participants72 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06199076 | Start2023 | PhasePhase 2 | ConditionsSubstance use and addiction | Participants206 | Lead sponsorOther | StatusStopped early | Library tests named
|
Questions, answered from the data
How many substance use and addiction trials use Delay Discounting?
104 registered substance use and addiction studies on ClinicalTrials.gov name it in an outcome measure, 34 of them in a primary outcome: 12% of the condition's 895 studies with a cognitive outcome, against 2% of all of them. It is the 2nd most named test in substance use and addiction trials.
Which tests do substance use and addiction trials use with Delay Discounting?
The Purchase Task (14 studies), the Stop-Signal Task (11 studies) and Balloon Risk (9 studies).
How many participants do phase 2 substance use and addiction trials that use Delay Discounting enroll?
Half of the phase 2 studies that name it enroll 76 participants or fewer, and the middle half enroll 41 to 151. 12 of them give a size.
When do substance use and addiction trials measure Delay Discounting?
Half of the primary outcomes that name Delay Discounting are measured within 4 weeks of the start, and the middle half from 4 days to 8 weeks. 30 primary outcomes give a duration.
How many completed substance use and addiction trials that use Delay Discounting have reported results?
36 of the 59 completed studies that name it, 61%, have reported results: 28 posted them on ClinicalTrials.gov, 18 have a results paper linked to the registry record, and 10 did both. The other 23 show neither. Of all completed studies with a cognitive outcome, 46% have reported results.
How the studies are counted
For each test family, the census runs ClinicalTrials.gov's own outcome search for the family's names and reads every study first posted by the day the family was counted. These studies were read on 10 November 2026. A study counts once on a page, however many tests it names. Counts for a test cover every version of the task under any of its names, so a page can count studies that used a commercial version.
The census adds two things to each record and changes nothing in it: which outcome list names the test (primary, then secondary, then other), and the condition groups, matched on the study's condition names and MeSH terms. A study can fall in several groups; one whose only condition is cognitive impairment or decline falls in “Cognitive impairment and decline”. Studies that name only instruments outside the library count in every total and share but are not listed.
A second read on 10 November 2026 added each study's overall status, whether results are posted, its intervention types, the countries of its sites and the time frame of the outcome that names each test. A time frame counts by the latest time point it names: “Baseline, 12 and 24 weeks” is 24 weeks, a single visit is within a day, and one that names no duration, such as “end of treatment”, is left out of the timings.
A third read on 10 November 2026 added the papers the registry links to each study: those its sponsor lists as reporting results, and those PubMed links to it through the study's NCT number. A study has a results paper when one of them came out in or after the month of its primary completion and PubMed does not class it as a protocol, review or comment. A paper that never gives the NCT number is not linked, so some studies counted as reporting neither did publish.
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine, which does not endorse these pages. Every study line is in the data release 2.1.0, and the explorer's own file is clinical-trials-studies.json.
The census counts Delay Discounting and Food Delay Discounting as one test family, so this page counts their studies together.
Run Delay Discounting in your trial
Choose tests with a record in registered trials, and run them in a browser at every site, on the same version each visit.